ABSTRACT
Background APOE is a major susceptibility gene for Alzheimer’s disease (AD). Recent studies in Europe and the US have identified rare missense variants (RMVs) in APOE which are significantly associated with AD. However, little is known regarding APOE RMVs in East Asians, including the Japanese, and their association with AD and lipid metabolism.
Objective To identify APOE RMVs in the Japanese population and investigate their association with AD and lipid metabolism, including low-density lipoprotein cholesterol levels.
Subjects APOE RMVs were explored in the NIG (2,589 subjects) and ToMMo (3,307 subjects) cohorts. A case-control study was performed involving 6,471 AD and 20,270 control subjects.
Methods Sanger sequencing or whole-exome sequencing was performed on NIG subjects. We used genotype data from ToMMo. APOE RMV frequencies in the Japanese were compared with various ethnic populations. Associations among APOE RMV genotypes, AD, and lipoproteins were examined.
Results Fourteen RMVs were identified (minor allele frequency 0.02 – 0.73%), 10 of which were specifically found in East Asians. Five RMVs previously reported overseas were not detected in Japanese individuals. Two RMVs (rs140808909 and rs190853081) exhibiting complete linkage disequilibrium were associated with AD protective effects: PBonferroni = 3.63E-02, OR (95% CI) = 0.70 (0.54–0.92). No significant differences in cholesterol levels were observed between RMV carriers and non-carriers.
Conclusions APOE RMVs were identified in the Japanese population, with two showing potential protective effects against AD. Further studies involving larger cohorts are required to confirm our findings and investigate the role of APOE RMVs in AD and lipid metabolism.
Introduction
Alzheimer’s disease (AD) is the leading cause of dementia in elderly individuals. AD is a multifactorial disease resulting from the interaction between environmental factors and individual genetic susceptibility. A large twin epidemiological study in Sweden estimated the heritability of AD to be 60–80%. 1 Multiple loci are suggested to contribute to the onset of AD. 2 This indicates that genetic factors play a significant role in the development and progression of AD. Large-scale genome-wide association studies (GWAS) have identified 90 susceptibility genes/loci for AD. 3 Recent studies have focused on applying polygenic risk score analysis 4–6 and polygenic resilience score analysis 7, which integrate multiple AD susceptibility variants to evaluate individual risks, with potential clinical applications being explored.
Among the AD susceptibility genes/loci identified to date, APOE is the most powerful and explanatory gene across various populations. 8–11 A search for “Alzheimer” on the GWAS Catalog website 12 reveals that the genomic region containing APOE shows a remarkably strong association and is a “multiple hit locus” with numerous variants associated with AD. Recently, rare missense variants (RMVs) of APOE have been reported to be associated with AD, shedding light on new links between APOE and AD. For example, RMVs such as p.L46P (p.L28P; rs769452 [Pittsburgh]) 13, p.R154S (p.R136S; rs121918393 [Christchurch]) 14, p.R163C (p.R145C; rs769455) 15, p.V254E (p.V236E; rs199768005 [Jacksonville]) 16, and p.R269G (p.R251G; rs267606661) 17 have been reported in Western populations, showing resistance to amyloid-ß (Aß), phosphorylated tau protein, or the APOE-e4 allele. Rasmussen et al. 18 identified 20 APOE RMVs in an analysis involving more than 100,000 participants and demonstrated their association with plasma APOE levels and AD onset.
However, there have been few reports regarding the identification and significance of APOE RMVs in the Japanese population. Therefore, this study was the first attempt at identifying APOE RMVs in the Japanese population. Here, we examined the genetic association between the identified RMVs and AD. Moreover, we investigated whether there were differences in peripheral blood lipoprotein levels between carriers and non-carriers of these RMVs.
Subjects And Methods
Subjects for identifying APOE RMVs
We explored APOE RMVs in two Japanese cohorts (Table 1). The first cohort, referred to as the NIG, consisted of 2,589 participants (1,150 females and 1,439 males) from medical and research institutions across Japan. This cohort was primarily established for research-level genetic diagnoses, including AD and various other neurological disorders. Of these, 826 cases were based on clinical diagnoses, and 1,763 were based on pathological diagnoses. Additionally, 508 of the 2,589 NIG subjects were derived from the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI). 19 Sanger sequencing (SS), whole-exome sequencing (WES), and a combination of both (SS + WES) were performed on 839, 1,509, and 241 subjects, respectively. The second cohort, referred to as ToMMo, consisted of 3,307 community-dwelling healthy subjects (1,810 females and 1,497 males) recruited by the Tohoku Medical Megabank Organization. 20 In compliance with the data usage policy (Research ID: 2019-0074), individual genotype data for 176 variants within a genomic region of approximately 7.2 kb, including APOE (positioned at 45,407,254 – 45,414,449 bp in GRCh37/hg19), were obtained. The total number of subjects from both cohorts was 5,896 (2,960 females and 2,936 males), with participants aged ≥20 years (mean: 64.1 years, median: 66.0 years, range: 20–111 years).
This study was approved and conducted according to the ethical guidelines of the Ethics Committee of Niigata University and all participating medical and research institutions (approval number of the Genetic Ethics Review Committee, Niigata University: G2017-0012, G2018-0034, 2018-0409, and G2022-0009).
SS for APOE
SS was performed in 1,080 subjects from the NIG cohort (839 SS; 241 SS + WES) (Table 1). Genomic DNA was extracted from peripheral blood or autopsied brain tissues and quantified using the NanoDrop spectrophotometer (Thermo Fisher Scientific). DNA quality was assessed by calculating the DNA integrity number (Agilent Technologies). The primers used for sequencing the entire coding region of APOE is provided in Supplementary Table 1.
WES
WES was performed on 1,750 participants from the NIG (1,509 for WES and 241 for SS + WES) (Table 1). Genomic DNA was used to prepare an exome library using the SureSelect Human All Exon V6 Kit (Agilent Technologies). The library was sequenced on an NovaSeq 6000 platform (Illumina) in 151-cycle paired-end mode. Sequence reads were processed with fastp (v.0.19.5) using the default settings for quality control and adapter trimming. The cleaned reads were then mapped to the human reference genome (hg38) using BWA-MEM (v.0.7.15-r1140) with default parameters. Subsequent analyses, including read processing, variant calling, and filtration, were performed following GATK4 Best Practices. The resulting variant call sets were annotated using snpEff (v.4.3t) and stored in an SQLite database using GEMINI (v.0.20.1).
Determination of six common APOE genotypes
We determined six common APOE genotypes (e2*2, e2*3, e2*4, e3*3, e3*4, and e4*4) in all 5,896 subjects from the NIG and ToMMo cohorts (Table 1) based on nucleotide combinations (haplotypes) of the common missense variants rs429358 (T>C: p.C130R [p.C112R]) and rs7412 (C>T: p.R176C [p.R158C]) in APOE. For the NIG cohort, these genotypes were determined using both the SS and TaqMan methods. Information regarding the TaqMan assays used (TaqMan assay IDs: 19AyD0001 for rs429358 and 19AyD0002 for rs7412) is provided in Supplementary Table 1. For the ToMMo cohort, genotypes were determined based on digital data (genotype: 0/0, 0/1, and 1/1). The results are presented in Table 1. The risk effects of APOE genotypes and alleles in Japanese patients with AD are shown in Supplementary Figure 1. APOE genotype and allele information reported by Asanomi et al. 21 was used in this analysis.
Case-control study
We conducted a case-control study to examine whether the identified APOE RMVs were genetically associated with AD. Information concerning the subjects used in this analysis is provided in Table 3, including sex, age (age at testing/death), and APOE genotype. Genomic variants for each subject were comprehensively genotyped using an Asian Screening Array (ASA) (Illumina). The number of samples analyzed by the ASA was 6,471 patients with AD and 20,270 control subjects.
None of the 14 APOE RMVs identified in the NIG and ToMMo cohorts were included in the ASA. Therefore, genotypes were inferred through imputation for each subject. We performed SNP imputation using Minimac4 with the Japanese reference panel, which was constructed from 1,000 Genomes Project Phase 3 data (1KGP3 [May 2013, n = 2,503]) and 3,181 Japanese whole-genome sequences from the National Center for Geriatrics and Gerontology (NCGG) biobank database. Variants with an INFO score ≥ 0.3 were included in the association analysis. Among the 14 APOE RMVs, genotype data were obtained for 4 variants (rs121918392 [e5], rs762461580, rs140808909 [e7], and rs190853081 [e7]) (Table 4).
TA cloning to verify RMV alleles
In one case (Subject ID #35: female, age range at death 90-99, e3*3) with three APOE RMVs (all heterozygous: rs267606663-G/a, rs140808909 [e7]-G/a, rs190853081 [e7]-G/a) (Supplementary Table 5), we investigated whether these RMVs were located on the same chromosome. All the RMVs were located in exon 4 of APOE. Genomic DNA from the subject was used as a template for PCR, followed by TA cloning (TaKaRa Mighty TA-cloning Kit). The sequences of the primer pair used for PCR were as follows: forward primer 5 ‘-TGCCGATGACCTGCAGAA-3’, and the reverse primer was 5’-GCTGCATGTCTTCCACCAG-3’.
Lipoprotein data collection
Measurement data for total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were available for the J-ADNI subjects included in the NIG (508 cases: baseline) and ToMMo (TC: 234 subjects; non-TC: 1,630 subjects). We examined the quantitative differences between APOE RMV carriers and non-carriers, if any.
Statistical analysis
Differences in sex distribution and APOE genotypic and allelic distributions between cases (AD) and controls were assessed using Fisher’s exact test based on 2×2 or 2×3 contingency tables (Table 3, Supplementary Table 4). Additionally, unadjusted odds ratios (OR) and 95% confidence intervals (95% CI) were calculated (Table 3, Supplementary Table 4). For age, unpaired Student’s t-test with Welch’s correction was used (Table 3).
Logistic regression analysis was conducted on APOE RMVs in the case-control study, with sex, age, and principal components as covariates to calculate P-values and ORs (95% CI) (Table 4). The Bonferroni method was applied to adjust for multiple comparisons and corrections were made for the four APOE RMVs in the ASA analysis.
A meta-analysis was conducted to integrate and assess the association between APOE genotypes/alleles and AD derived from the two cohorts as described in a study by Asanomi et al. 21: the NCGG and the Japanese Genetic Study Consortium for Alzheimer’s Disease (JGSCAD) 29 (Supplementary Figure 1). Both fixed-effects and random-effects models were assumed, and Chi-square P-values, pooled ORs, and 95% CIs were calculated. Cochran’s Q statistic and I² statistic were also computed to evaluate heterogeneity between the two datasets.
Comparisons of TC, LDL-C, HDL-C, TG, and the LDL-C/HDL-C (LH) ratio between the two groups (APOE RMV carriers vs. non-carriers) were conducted using the non-parametric Mann-Whitney U-test (Supplementary Figure 4).
The series of genetic statistical analyses related to the case-control study (Table 4, Figure 2) were conducted using PLINK (v.1.90; https://www.cog-genomics.org/plink/). 30 Meta-analysis (Supplementary Figure 1) was conducted using StatsDirect (v.4.0.4; https://www.statsdirect.com). Other statistical analyses (Tables 1 and 3, Supplementary Table 4, Figure 3, Supplementary Figure 4) were performed using GraphPad Prism software (v.10.3.1; https://www.graphpad.com). P-values less than 0.05 were considered statistically significant.
The 14 APOE RMVs identified in this study have been added to the Alzforum MUTATIONS APOE diagram (https://www.alzforum.org/mutations/apoe). RMVs identified in both ToMMo and NIG cohorts are marked in red, whereas those identified only in ToMMo are marked in magenta.
Of the 14 APOE RMVs identified in this study, four imputed variants were included in the analysis. Two RMVs, rs140808909 and rs190853081, which were in complete LD and were defined as the e7 allele, remained statistically significant after multiple comparison corrections. The OR was < 1.0, suggesting a protective effect against AD. Detailed numerical data are presented in Table 4.
For the four APOE RMVs analyzed in the case-control study (Table 4, Figure 2), we conducted a case-control analysis focusing on subjects carrying alternative alleles, examining APOE genotypes (A) and alleles (B). A forest plot showing ORs and 95% CIs is provided. For genotypes (A), the OR (95% CI) of e3*4 relative to e3*3 was calculated. For alleles (B), the OR (95% CI) of e4 relative to e3 was calculated. Bold text indicates that the 95% CI of the OR does not include 1.00. “All” indicates the OR and its 95% CI for all samples (6,471 AD cases and 20,270 controls) as shown in Table 3. Ref, reference.
Databases
Databases and analysis websites used in this study are listed below in alphabetical order.
Alzforum MUTATIONS APOE: https://www.alzforum.org/mutations/apoe
Ensemble Human (GRCh38.p14): https://asia.ensembl.org/Homo_sapiens/Info/Index
gnomAD (v4.1.0): https://gnomad.broadinstitute.org
GWAS Catalog: https://www.ebi.ac.uk/gwas/home
UCSC genome: https://genome.ucsc.edu
Results
Identification of APOE RMVs in the Japanese population
Using 2,589 subjects from NIG (Table 1), we identified seven APOE RMVs (Table 2, Figure 1): rs1969812567 (p.A7P), rs121918392 (p.E21K), rs762461580 (p.R50H), rs370594287 (p.Q64H), rs267606663 (p.R242Q), rs140808909 (p.E262K), and rs190853081 (p.E263K). All carriers were heterozygous, and no homozygotes were identified. A summary of the clinical and pathological diagnostic information of these patients is provided in Supplementary Table 5. Among these seven RMVs, the two variants with the highest alternative allele frequencies were rs140808909 (p.E262K) and rs190853081 (p.E263K), both with a minor allele frequency (MAF) of 0.00657 (Table 2). These two variants were in complete linkage disequilibrium (LD) (LD coefficient R² = 1), indicating that they were fully co-inherited (Supplementary Figure 2). Both variants were previously identified in Japanese patients with dyslipidemia and atherosclerosis, defined as the APOE-e7 allele. 22–24 rs121918392 (p.E21K) was defined as the APOE-e5 allele 22, 25–27 and was the third-most frequent variant after the APOE-e7-defining rs140808909 (p.E262K) and rs190853081 (p.E263K), with an MAF of 0.00348 (Table 2). rs121918392 (p.E21K) was also associated with dyslipidemia and atherosclerosis. 22, 25–27
In an analysis of 3,307 subjects from the ToMMo cohort (Table 1), we identified 14 APOE RMVs (Table 2, Figure 1). Seven variants were identified in both the NIG and ToMMo cohorts. Additionally, seven variants were found in the ToMMo cohort but not in the NIG cohort: rs201672011 (p.E31K), rs748703149 (p.G145S), rs954186991 (p.A156T), rs1339651557 (p.R185H), rs1969871875 (p.E186K), rs1385100920 (p.G206D), and rs767339630 (p.R278H). All carriers were heterozygous, and no homozygotes were identified. For two variants in complete LD, rs140808909 (p.E262K) and rs190853081 (p.E263K), we identified one homozygous individual: sex, male; age range at entry, 60-69 years; APOE genotype, e3*3; and body mass index, 23.0. This individual had LDL-C, HDL-C, and TG levels of 96, 49, and 67, respectively, all within normal ranges (TC data were not available).
Five previously reported variants, rs769452 (p.L46P: Pittsburgh) 13, rs121918393 (p.R154S: Christchurch) 14, rs769455 (p.R163C) 15, rs199768005 (p.V254E: Jacksonville) 16, and rs267606661 (p.R269G) 17 (Figure 1), were not detected in either NIG or ToMMo cohorts (Table 2). Furthermore, these variants were not observed in the Japanese multi-omics database jMorp (54 KJPN, 38 KJPN, and 14 KJPN) 28 (Supplementary Table 3). These variants are predominantly observed in non-East Asian populations.
Relationship between identified APOE RMVs and common APOE alleles, e2, e3, and e4
Clarifying the common APOE alleles (e2, e3, and e4) on which each identified APOE RMV is located is crucial for understanding any potential genetic relationship between AD and APOE. Therefore, for each APOE RMV, we categorized subjects from the NIG and ToMMo cohorts (Table 1) according to the common APOE genotypes: e2*2, e2*3, e2*4, e3*3, e3*4, and e4*4 (Supplementary Table 2). The most common APOE genotype among APOE RMV carriers was e3*3. Several individuals were also identified with e3*4 and e2*3, and one individual with e4*4. None of the APOE RMV carriers were found with e2*2 or e2*4. The variant rs121918392 (p.E21K), which defines the e5 allele, and two variants rs140808909 (p.E262K) and rs190853081 (p.E263K), which are in complete LD and define the e7 allele, appeared to co-segregate with the e3 allele (Supplementary Table 2). The rs767339630 (p. R278H) variant was found in a subject with e4*4, suggesting that this variant is likely to co-segregate with the e4 allele (Supplementary Table 2).
Ethnicity dependent frequencies of APOE RMVs
To investigate whether the 14 APOE RMVs identified in the NIG and ToMMo cohorts exist in other populations and to assess their frequencies, we explored public databases (Supplementary Table 3). First, we examined the jMorp database. 28 Alternative alleles were observed in all 14 variants. For the two variants in complete LD, rs140808909 (p.E262K) and rs190853081 (p.E263K), several homozygous individuals were identified: twelve in 54 KJPN, six in 38 KJPN, and three in 14 KJPN. This result was consistent with our analysis, which showed that these two APOE RMVs had the highest alternative allele frequencies. The other 12 variants were observed only in heterozygous individuals.
Four variants, rs201672011 (p.E31K), rs762461580 (p.R50H), rs370594287 (p.Q64H), and rs748703149 (p.G145S), were also found in populations other than East Asian ones (Supplementary Table 3). In contrast, six variants, rs121918392 (p.E21K), rs954186991 (p.A156T), rs1339651557 (p.R185H), rs267606663 (p.R242Q), rs140808909 (p.E262K), and rs190853081 (p.E263K), were highly ethnicity-dependent and observed only in the East Asian population (Supplementary Table 3). Information regarding frequencies of the four variants, rs1969812567 (p.A7P), rs1969871875 (p.E186K), rs1385100920 (p.G206D), and rs767339630 (p.R278H), was not available for other populations (Supplementary Table 3).
Effect of APOE RMVs on AD
To investigate whether the 14 identified RMVs (Table 2, Figure 1) were genetically associated with AD, we conducted a case-control study involving 6,471 AD cases and 20,270 controls (Table 3). Of the 14 RMVs, examined, there were four variants for which genotype data were obtained by imputation. Two variants, rs140808909 (p.E262K) and rs190853081 (p.E263K), that define the e7 allele, showed a statistically significant association with AD (Table 4). Since these two RMVs are in complete LD, they exhibited the same P-values and OR (95% CI): PUnadjusted = 8.95E-03, PBonferroni = 3.58E-02, and OR (95% CI) = 0.70 (0.54 – 0.92) (Table 4, Figure 2). An OR < 1.00 suggests that the e7 allele may have a protective effect against AD.
Association between APOE genotypes/alleles and AD in APOE RMV carriers
By focusing on carriers of the four RMVs analyzed in the case-control study (Table 4), we investigated whether APOE genotypes and alleles were associated with AD. Because no carriers of APOE RMVs with the e2*2, e2*4, or e4*4 genotypes were identified, they were excluded from analysis. Additionally, owing to the low frequency of the e2*3 genotype and e2 allele, they were excluded from analysis. As a result, the comparison of genotypes focused on e3*3 and e3*4, and we compared e3 and e4 for alleles. Results of the analyses are presented in Figure 3 and Supplementary Table 4. For reference, the OR (95% CI) including both carriers and non-carriers of APOE RMVs, denoted as “All,” were also provided, derived from the data in Table 3. The OR (95% CI) for both APOE genotypes and alleles exhibited similar trends. Specifically, for the three RMVs defining the e5 (rs121918392) and e7 (rs140808909 and rs190853081) alleles, there was a tendency for reducing the risk of the e4 allele. For example, in a comparison between the e3*3 and e3*4 genotypes, the OR (95% CI) for All was 3.04 (2.85-3.24), whereas it was 2.20 (1.01-4.95) for e5 (rs121918392). In contrast, for rs762461580, there was a slight increase in risk associated with the e4 allele. For example, in the same genotype comparison, the OR (95% CI) for All was 3.04 (2.85-3.24), but was 3.78 (1.05-12.54) for rs762461580.
Comparison of Lipoprotein Levels Between APOE RMV Carriers and Non-Carriers
We compared blood lipoprotein levels between carriers and non-carriers of APOE RMVs in J-ADNI participants (508 subjects) from the NIG cohort and in participants from the ToMMo cohort (TC: 234 subjects; and non-TC: 1,630 subjects). No statistically significant differences were observed between APOE RMV carriers and non-carriers in terms of TC, LDL-C, HDL-C, TG, or LH ratios (Supplementary Figure 4).
Discussion
In this study, we identified 14 APOE RMVs among 5,896 Japanese individuals (Table 2, Figure 1). We found that some APOE RMVs were specific to East Asians, including Japanese (Supplementary Table 3). Notably, variants previously reported in Western populations (Christchurch 14 and Jacksonville variants 16) were completely absent in the Japanese population (Table 2, Supplementary Table 3). These findings suggested that RMVs have distinct ethnic and regional specificities. To investigate their genetic association with AD, we conducted a case-control study involving 26,741 individuals (Table 3). Two APOE RMVs, rs140808909 and rs190853081, which were in complete LD (Supplementary Figure 2) and defined as the e7 allele 22–24, showed a statistically significant association with AD, with a protective effect (Table 4, Figure 2). To the best of our knowledge, this association between APOE RMV and AD is the first of its kind in East Asians. Future studies with larger sample sizes are strongly recommended to validate these findings, as reproducibility is a critical focus. Considering the genetic diversity and ethnic specificity of the genomic variants 31, detailed analyses of each ethnic group are important.
In this exploratory study, we identified 14 APOE RMVs (Table 2, Figure 1), with the e7 allele 22–24 being the most intriguing because of its potential protective effects against AD. The two RMVs that define the e7 allele replace two glutamate (E) residues with lysine (K) at the entry point of the lipid-binding domain on the C-terminal side of APOE (Figure 1). This substitution reduces the binding affinity of e7 to LDL receptors and increases its affinity for heparin. 32 No previous studies have reported a genetic association between e7 and AD. However, Youn et al. 33 suggested that the e7 allele may be involved in cognitive impairment, based on a study of 344 amnestic patients and 345 controls in a Korean population. They identified three heterozygous carriers of the e7 allele, all of whom belonged to the amnestic group. Two of these individuals were clinically diagnosed with AD and small vessel disease, and the remaining one was diagnosed with subjective cognitive impairment. They also predicted the three-dimensional protein structure of e7, showing that its C-terminal structure resembled that of e4, despite having an e3 background. They concluded that e7 might behave like e4 and potentially exert adverse effects on cognitive function. While our study suggests a protective effect of the e7 allele against AD, the relationship between cognitive function and the e7 allele is an important area for future investigation.
We compared peripheral blood cholesterol levels (TC, LDL-C, HDL-C, TG, and LH ratios) between carriers and non-carriers of the identified APOE RMVs. Contrary to expectations, no significant differences were observed in cholesterol levels (Supplementary Figure 4). Owing to the rarity of APOE RMVs, all carriers were grouped into a single category for analysis in this study. Different APOE RMVs may have varying effects on peripheral blood cholesterol levels; ideally, each APOE RMV should be analyzed separately. For instance, a study concerning the e5 and e7 alleles revealed a trend toward higher TC (> 220 mg/dL) and TG (> 150 mg/dL) levels compared with controls. 34 Considering the low population frequency of APOE RMVs (< 1%), comparative analyses with larger sample sizes are warranted.
This study had certain limitations. First, the number of identified RMVs (Table 2, Figure 1) was lower than expected, and further exploratory studies using a larger sample of Japanese individuals are needed. Specifically, if the focus is on late-onset AD, exploratory studies of RMVs using samples from older individuals, particularly those aged 65 and above, would be valuable. Second, we were unable to verify the reproducibility of the genetic association between AD and the e7 allele (rs140808909 and rs190853081) in a larger independent sample of Japanese individuals, which warrants further investigation. Third, because this study was based on cross-sectional data, the longitudinal relationship between RMVs and the risk of developing AD remains unclear. Finally, functional assays of RMVs have not yet been conducted, leaving the impact of RMVs on AD pathology and the underlying molecular mechanisms unclear.
APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aß and tau. 35–36 Previous research has largely focused on the major missense alleles, e2, e3 and e4, of APOE. In addition to the major APOE missense variants, research on APOE RMVs, including the Christchurch variant (rs121918393: p.R154S [p.R136S]) 14, 37–41, is expected to expand, further deepening our understanding of the role of APOE in AD pathophysiology. Additional studies are required to elucidate the functional significance of the 14 APOE RMVs identified in this study.
Author Contributions
AM and TIkeuchi: Study design, data analysis, interpretation of data, and manuscript preparation and revision. AO, NH, TT, MH, KK, and MK: Nucleic acid extraction, quality control, sequencing, genotyping analyses, data interpretation, and manuscript revision. RM, SN, and KO: case-control studies using gene chips, data interpretation, and manuscript revision. DK, YH, TS, MTakao, RG, MTada, AK, AArakawa, MM, SM, YS, HH, TM, AAkagi, YR, HM, JS, MY, and HY provided the autopsied brains and revised the manuscript. RK and TIwatsubo: Data interpretation and manuscript revision. All authors have read and approved the final version of the manuscript.
FUNDING
This study was supported by: (1) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 21K07271 (AM); (2) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (B), 21H03537 (AM); (3) AMED, JP21dk0207055 (AM); (4) JSPS Grant-in-Aid for Scientific Research (KAKENHI), 22H04923 (DK); (5) AMED, JP21wm0425019 (MT); (6) Intramural fund from NCNP, Grant Number 6-8 (MT); (7) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 18K06506 (MT); (8) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 21K06417 (MT); (9) JSPS Grant-in-Aid for Transformative Research Areas, 22H04923 (MT); (10) the Research Committee of Prion Disease and Slow Virus Infection, the Ministry of Health, Labour and Welfare Health and Labour Sciences Research Grants, Japan (MT); (11) AMED, JP24wm0425019 (AK) ; (12) AMED, JP21wm0425019 (YS, SM); (13) JSPS Grant-in-Aid for Scientific Research (KAKENHI), 22H04923 (CoBiA) (YS); (14) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 22K07550 (YS); (15) MHLW Research on rare and intractable diseases Program Grant Number JPMH23FC1008 (YS); (16) AMED, JP21wm0425019 (MY); (17) AMED, JP18kk0205009 (SN); (18) AMED, JP21dk0207045 (SN); (19) AMED, JP22dk0207060 (SN); (20) AMED, JP21dk0207045 (KO); (21) AMED, JP22dk0207060 (KO); (22) Research Funding for Longevity Sciences from NCGG (24-15) (KO); (23) a grant from the Japanese Ministry of Health, Labour, and Welfare for Research on Dementia (KO); (24) AMED, JP23wm0525019 (MK); (25) AMED, JP23dk0207060 (MK); (26) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (B), 23K27515 (TIwatsubo); and (27) AMED, JP22dk0207060 (TIkeuchi)
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
Supplementary Material
Supplementary figures and tables are available in the electronic version of this article.
Data Availability
The data supporting the findings of this study are generally available upon request from the corresponding authors (AM and TIkeuchi). However, the WES data used in this study are not publicly available due to privacy or ethical restrictions.
Supplementary Table 1. SS primers for all APOE exons and TaqMan SNP genotyping assays for rs429358 and rs7412.
Supplementary Table 2. APOE RMV carriers expanded based on six common APOE genotypes.
Supplementary Table 3. Details of 14 RMVs identified in this study and 5 RMVs previously reported elsewhere.
Supplementary Table 4. Case-control study on APOE RMVs identified.
Supplementary Table 5. Clinical and neuropathological diagnoses of APOE RMV carriers in the NIG cohort. sample
Supplementary Figure 1. Meta-analysis of APOE genotypes and alleles in NCGG and JGSCAD.
A meta-analysis was conducted using APOE genotype data from two Japanese cohorts, the NCGG (Table S2) and JGSCAD (Table S4), as reported by Asanomi et al. 21 The pooled ORs and its 95% CI were calculated using both fixed effects (Fixed) and random effects (Random) models, and are presented in a forest plot. For genotype analysis (A), the OR and 95% CI for five genotypes (e2*2, e2*3, e2*4, e3*4, e4*4) were calculated in comparison to e3*3. For allele analysis (B), the OR and 95% CI for two alleles (e2 and e4) were calculated in comparison to e3. The OR and 95% CI are highlighted in bold if the 95% CI does not include 1.00. Ref, reference.
Supplementary Figure 2. Pairwise LD measures between two APOE RMVs, rs140808909 and rs190853081, determining the e7 allele.
Using the LDpair Tool on the LDlink website (https://ldlink.nih.gov/?tab=ldpair), we analyzed the haplotypes and their frequencies, as well as the strength of LD (D’ and R²) between the two RMVs, rs140808909 and rs190853081, in the East Asian (EAS) population (504 subjects). Sub-analyses were conducted separately for the Japanese in Tokyo, Japan (JPT, 104 subjects) and the Southern Han Chinese (CHS, 105 subjects) populations. Three A-A haplotypes were observed in the EAS population, one in JPT, and two in CHS. Notably, these two RMVs were not detected in populations outside the EAS database.
Supplementary Figure 3. Sequence verification in an individual carrying three APOE RMVs: p.Arg242Gln (rs267606663-G/a), p.Glu262Lys (rs140808909-G/a), and p.Glu263Lys (rs190853081-G/a).
Subject ID #35 (APOE genotype, e3*3; Supplementary Table 5) harbored three RMVs. The results of SS of the genomic DNA are shown in A. Three RMVs (rs267606663, rs140808909, and rs190853081) were detected, all of which were G/A heterozygotes. PCR products generated using genomic DNA as a template were cloned into a TA vector and SS of the plasmid DNA was performed. The results are presented in Section B. It was found that the alternative allele “a” of rs267606663 (G/a) does not co-segregate with the alternative alleles “a” of the other two RMVs, rs140808909 (G/a) and rs190853081 (G/a), and is located independently on a different chromosome. Asterisks indicate nucleotide substitutions; black represents the reference allele, and red represents the alternative allele.
Supplementary Figure 4. A comparison of TC, LDL-C, HDL-C, and TG levels and L/H ratios between APOE RMV carriers and non-carriers in the J-ADNI and ToMMo cohorts.
Each measurement item is represented as a box-and-whisker plot (whiskers, 5th to 95thpercentiles; +, mean) divided into J-ADNI and ToMMo groups and further subdivided into APOE RMV carriers and non-carriers. Numbers in parentheses indicate the sample size for each group. The light blue vertical lines indicate reference values for each measurement item: A, TC 150–219 mg/dL; B, LDL-C 70–139 mg/dL; C, HDL-C 40–96 mg/dL [females 40–96 mg/dL, and males 40–86 mg/dL]; D, TG 50–149 mg/dL; and E, LH ratio ≤1.5. No significant differences were observed in any of these comparisons. PMW, P-value of Mann-Whitney U-test.
ACKNOWLEDGMENTS
We wish to thank all of the participants for their involvement in this study. We also gratefully acknowledge the ToMMo cohort (Table 1) for providing individual genomic variant data on APOE and its surrounding regions as well as various datasets from the subjects (research ID: 2019-0074). In the preparation of this paper, an initial rough English proofreading was performed using ChatGPT-4o, followed by proofreading by a native speaker of English.
References
